The KCTD9 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population generated from the CAL-27 human tongue squamous cell carcinoma line. This product enables loss-of-function studies of KCTD9, a gene encoding an E3 ubiquitin ligase substrate adaptor, within a well-characterized oral cancer model. The polyclonal nature of the knockout pool preserves the heterogeneous genetic background typical of tumor cell populations, making it a versatile tool for investigating gene function without clonal selection bias.
The parental CAL-27 cell line is an epithelial cell model derived from a human tongue squamous cell carcinoma, widely used to study molecular mechanisms of oral tumorigenesis and progression. It provides a biologically relevant context to assess the role of KCTD9 in oral cancer, harboring genetic alterations common to this malignancy and exhibiting robust tumorigenic properties.
KCTD9 functions as a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, promoting ubiquitination and subsequent proteasomal degradation of target proteins, including ??-catenin. By interacting with CUL3, KCTD9 facilitates ??-catenin ubiquitination, leading to its degradation and thereby negatively regulating Wnt/??-catenin signaling. This positions KCTD9 at the nexus of the ubiquitin-proteasome system and Wnt/??-catenin pathway, a regulation critical for normal cellular homeostasis and often dysregulated in cancer, influencing processes such as proliferation and apoptosis.
In CAL-27 oral squamous cell carcinoma cells, KCTD9 knockout disrupts the normal regulatory circuit controlling ??-catenin turnover, potentially altering Wnt/??-catenin pathway activity. This polyclonal model allows examination of how KCTD9 loss affects ??-catenin levels, target gene transcription, and cancer-associated phenotypes including proliferation, survival, and migration, while avoiding clonal artifacts and better reflecting tumor heterogeneity.
This knockout model is applicable to cancer biology, Wnt pathway analysis, tumor suppressor functional studies, and drug target validation. Researchers can employ biochemical assays including western blotting, RT-qPCR, co-immunoprecipitation, and ubiquitination assays to characterize KCTD9 interactions and ??-catenin regulation. Functional readouts are provided by TOP/FOP luciferase reporter assays, MTT, colony formation, apoptosis, and migration assays. For further details, please contact Ascent Research.
